Zimmer Biomet stock (US98956P1021): Leader in orthopedic devices

Zimmer Biomet focuses on developing orthopedic reconstructive products, sports medicine, biologics, extremities, trauma, spine, and dental solutions. The company reported full-year 2025 revenue of $7.53 billion in its February 2026 earnings release, up 4.3% from the prior year on a reported basis and 5.2% adjusted, according to Zimmer Biomet IR as of Feb 6, 2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Zimmer Biomet: core business model

Zimmer Biomet Holdings, Inc. designs, manufactures, and markets orthopedic reconstructive products, sports medicine, biologics, extremities, trauma, spine, craniomaxillofacial, and dental products. The company operates through four main segments: Knee, Hips, S.E.T. (Sports, Extremities, Trauma), and Dental. Its portfolio includes leading knee systems like Persona and Oxford, hip solutions such as G7 and Continuum, and advanced digital technologies like ROSA Robotics.

The business model emphasizes innovation in implants and surgical tools to address musculoskeletal conditions affecting millions worldwide. In 2025, the company served over 100 countries, with the U.S. representing about 55% of revenue, per its 10-K filing published in February 2026, according to SEC filing as of Feb 2026.

Main revenue and product drivers for Zimmer Biomet

Knee reconstruction is the largest revenue driver, accounting for roughly 37% of 2025 net sales at $2.79 billion, driven by high-volume procedures and premium implants. Hip products contributed $1.90 billion, benefiting from acetabular systems and robotic-assisted surgeries. S.E.T. segment sales reached $2.11 billion, fueled by sports medicine procedures post-COVID recovery and trauma fixation devices.

Dental revenue stood at $0.73 billion for the year. Growth in digital health, including the mymobility app and ROSA Shoulder application launched in 2025, supports procedure efficiency. U.S. market strength, with elective procedures up amid aging demographics, bolsters performance, as noted in the Q4 2025 earnings call transcript dated February 6, 2026.

Industry trends and competitive position

The global orthopedics market is projected to grow at 4-5% CAGR through 2030, driven by rising osteoarthritis cases, obesity, and active lifestyles increasing sports injuries. Zimmer Biomet holds a top-three position in knees and hips, competing with Stryker and Smith & Nephew. Its 2025 U.S. hip market share stood at around 25%, per company reports.

Robotics adoption is accelerating, with over 1,000 ROSA systems installed by end-2025. The company invests 7-8% of revenue in R&D annually, focusing on personalized implants via 3D printing and AI-driven planning, positioning it well in a market valued at $60 billion in 2025 according to IDC Health as of 2025.

Why Zimmer Biomet matters for US investors

Zimmer Biomet generates over half its revenue from the U.S., tying its fortunes to American healthcare spending and Medicare reimbursement policies. Listed on NYSE under ZBH, it offers exposure to the $200 billion+ U.S. medtech sector, where orthopedics demand rises with 10,000 Baby Boomers retiring daily. Stable dividend payouts, with $0.24 quarterly in 2025, appeal to income-focused investors.

Recent stock performance reflects sector resilience; shares traded around $105 USD on NYSE as of early May 2026, per market data portals. Its role in enabling mobility for aging Americans underscores relevance amid demographic shifts.

Conclusion

Zimmer Biomet maintains a strong foothold in orthopedics through innovative products and digital tools, with 2025 results showing steady growth across segments. Exposure to U.S. demographics and global expansion supports its position, though competition and regulatory changes remain factors. Investors track upcoming earnings and robotics adoption for insights into sustained performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.